Literature DB >> 28703701

Mutations in MmpL3 alter membrane potential, hydrophobicity and antibiotic susceptibility in Mycobacterium smegmatis.

Matthew B McNeil1, Devon Dennison1, Tanya Parish1.   

Abstract

MmpL3 is a promising target for novel anti-tubercular agents, with numerous compound series identified as MmpL3 inhibitors. Despite this, there is an incomplete understanding of MmpL3 function. Here we show that Mycobacterium smegmatis MmpL3 mutant strains had an altered cell wall hydrophobicity, disrupted membrane potential and growth defects in liquid media. Compensatory mutations that restored normal growth also returned membrane potential to wild-type. M. smegmatis MmpL3 mutant strains were resistant to two anti-tubercular agents, SQ109 and AU1235, but were more sensitive to rifampicin, erythromycin and ampicillin. Exposure of M. smegmatis to AU1235 affected the cell wall composition and increased the potency of rifampicin. However, MmpL3 mutants did not prevent the dissipation of membrane potential following exposure to SQ109. These results demonstrate that in M. smegmatis, MmpL3 contributes to a number of important phenotypes such as membrane potential, cell wall composition, antibiotic susceptibility and fitness.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28703701     DOI: 10.1099/mic.0.000498

Source DB:  PubMed          Journal:  Microbiology (Reading)        ISSN: 1350-0872            Impact factor:   2.777


  9 in total

1.  Utilization of CRISPR Interference To Validate MmpL3 as a Drug Target in Mycobacterium tuberculosis.

Authors:  Matthew B McNeil; Gregory M Cook
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Identification of New MmpL3 Inhibitors by Untargeted and Targeted Mutant Screens Defines MmpL3 Domains with Differential Resistance.

Authors:  John T Williams; Elizabeth R Haiderer; Garry B Coulson; Kayla N Conner; Edmund Ellsworth; Chao Chen; Nadine Alvarez-Cabrera; Wei Li; Mary Jackson; Thomas Dick; Robert B Abramovitch
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

3.  HC2091 Kills Mycobacterium tuberculosis by Targeting the MmpL3 Mycolic Acid Transporter.

Authors:  Huiqing Zheng; John T Williams; Garry B Coulson; Elizabeth R Haiderer; Robert B Abramovitch
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

Review 4.  Structural and Functional Diversity of Resistance-Nodulation-Cell Division Transporters.

Authors:  Philip A Klenotic; Mitchell A Moseng; Christopher E Morgan; Edward W Yu
Journal:  Chem Rev       Date:  2020-11-19       Impact factor: 60.622

5.  Direct Inhibition of MmpL3 by Novel Antitubercular Compounds.

Authors:  Wei Li; Casey M Stevens; Amitkumar N Pandya; Zbigniew Darzynkiewicz; Pankaj Bhattarai; Weiwei Tong; Mercedes Gonzalez-Juarrero; E Jeffrey North; Helen I Zgurskaya; Mary Jackson
Journal:  ACS Infect Dis       Date:  2019-03-28       Impact factor: 5.084

6.  Biological Profiling Enables Rapid Mechanistic Classification of Phenotypic Screening Hits and Identification of KatG Activation-Dependent Pyridine Carboxamide Prodrugs With Activity Against Mycobacterium tuberculosis.

Authors:  Melissa D Chengalroyen; Audrey Jordaan; Ronnett Seldon; Thomas Ioerger; Scott G Franzblau; Mohamed Nasr; Digby F Warner; Valerie Mizrahi
Journal:  Front Cell Infect Microbiol       Date:  2020-11-13       Impact factor: 5.293

Review 7.  Pleiotropic roles of late embryogenesis abundant proteins of Deinococcus radiodurans against oxidation and desiccation.

Authors:  Yingying Liu; Chen Zhang; Zhihan Wang; Min Lin; Jin Wang; Min Wu
Journal:  Comput Struct Biotechnol J       Date:  2021-06-04       Impact factor: 7.271

8.  Multiple Mutations in Mycobacterium tuberculosis MmpL3 Increase Resistance to MmpL3 Inhibitors.

Authors:  Matthew B McNeil; Theresa O'Malley; Devon Dennison; Catherine D Shelton; Bjorn Sunde; Tanya Parish
Journal:  mSphere       Date:  2020-10-14       Impact factor: 4.389

9.  Cryo-EM structure and resistance landscape of M. tuberculosis MmpL3: An emergent therapeutic target.

Authors:  Oliver Adams; Justin C Deme; Joanne L Parker; Philip W Fowler; Susan M Lea; Simon Newstead
Journal:  Structure       Date:  2021-07-08       Impact factor: 5.006

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.